Vitamin K antagonist
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Vitamin K antagonists (VKA) are a class of anticoagulants which, as their name indicates, act by inhibiting the action of vitamin K.
They can be teratogens.[1]
Coumarins
Coumarins are the most commonly used VKA, and sometimes the terms are used synonymously.
In medicine, the most commonly used VKA is warfarin.[2] The primary mechanism of warfarin is the inhibition of vitamin K epoxide reductase.
VKAs are also used as rodenticides.[3]
-
Warfarin or coumadin
Other VKAs
Not all VKAs are coumarins. For example, fluindione is a VKA,[4] but not a coumarin.
Another example is phenindione.[5]
Many of the non-coumarin VKAs are 1,3-indandione derivatives.
Tioclomarol is another VKA,[6] but it is neither a coumarin nor a diketone.
See also
References
- ↑ Schaefer C, Hannemann D, Meister R; et al. (2006). "Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study". Thromb. Haemost. 95 (6): 949–57. doi:10.1160/TH06-02-0108. PMID 16732373. Unknown parameter
|month=ignored (help) - ↑ Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008). "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID 18574265. Unknown parameter
|month=ignored (help) - ↑ Griminger P (1987). "Vitamin K antagonists: the first 50 years". J. Nutr. 117 (7): 1325–9. PMID 3302140. Unknown parameter
|month=ignored (help) - ↑ Mentré F, Pousset F, Comets E; et al. (1998). "Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients". Clin. Pharmacol. Ther. 63 (1): 64–78. doi:10.1016/S0009-9236(98)90122-9. PMID 9465843. Unknown parameter
|month=ignored (help) - ↑ "Foreword: contemporary issues in the management and treatment of atrial fibrillation -- Agnelli 7 (2005): C3 -- European Heart Journal Supplements". Retrieved 2008-12-22.
- ↑ "ATC/DDD Index". Retrieved 2008-12-23.